http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0069814-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a646c95502fcd84b5fa03b8b9d00baa8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35ff085d54f5c69e403ee2ff5b764e46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-46 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-46 |
filingDate | 2000-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91f10d3aa06a69a9794d8754cdac5c6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d9cca04aca53e873316fa020ad050cc |
publicationDate | 2000-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-0069814-A1 |
titleOfInvention | (e,3r)-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol |
abstract | The present invention relates to an (E,3R)-enantiomer of Formula (I) or a pharmaceutically-acceptable salt or in vivo-cleavable ester or ether thereof, substantially free of the enantiomeric (E,3S)-compound. The compound is a peripherally-selective antiandrogen. The invention also relates to a crystalline form of the enantiomer or the salt, ester or ether thereof. In addition, the present invention relates to a process for the preparation of all of these compounds, a pharmaceutical composition comprising the enantiomer, salt, ester, ether or crystalline form, and uses and methods employing the enantiomer, salt, ester, ether or crystalline form. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010267392-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8153788-B2 |
priorityDate | 1999-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.